Participating Authorities Sample Clauses

Participating Authorities. 7.1 The Contracting Authorities referred to in Schedule 8 are entitled to place Orders. For the avoidance of doubt, any successor bodies of those entities shall be entitled to place Orders and shall be deemed Participating Authorities for the purposes of this Framework Agreement. 7.2 NHS Service Providers shall be allowed to place Orders or the purchase of Goods pursuant to this Framework Agreement as if they were Participating Authorities provided that: 7.2.1 such Orders are strictly limited to the purchase of Goods required for the provision of Services to or on the behalf of the relevant Participating Authority pursuant to a NHS Service Agreement and the NHS Service Provider shall not otherwise onwards sell Goods bought pursuant to an Order to other third parties; 7.2.2 the relevant Participating Authority is ultimately responsible for reimbursing the NHS Service Provider for the cost of such Goods pursuant to the relevant NHS Service Agreement and that the costs to the Participating Authority does not (and shall not) exceed the Contract Price; 7.2.3 all supply of Goods by the Supplier to an NHS Service Provider shall be at the Contract Price; and 7.2.4 the relevant Participating Authority has provided its written consent to the NHS Service Provider awarding a Contract pursuant to this Framework Agreement and to the purchase of Goods and confirmed that such award and purchases are limited to the purchase of Goods needed for the provision of Services to the relevant Participating Authority pursuant to a NHS Service Agreement.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Participating Authorities. 5.1 For the purpose of this Agreement and the Community Diagnostic Hubs Framework, the following Contracting Authorities are considered to be Participating Authorities: 5.1.1 any Clinical Commissioning Group; 5.1.2 any NHS Trust or NHS Foundation Trust; and 5.1.3 the NHS Commissioning Board, and for the avoidance of doubt, any successor bodies of any of the entities described in this Clause 5 are also to be considered Participating Authorities.
Sample 1
Participating Authorities. 7.1 This DPS Framework Agreement will be accessible to the UK public sector bodies in England, Scotland, Wales and Northern Ireland (including any future successor organisation(s) to the functions exercised by any such organisation(s)) listed in Clause 7.2 of this Schedule 1A below. Non-Contracting Authorities will also be permitted to access this DPS Framework Agreement. 7.2 This DPS Framework Agreement may be accessed by the public sector bodies listed below to the extent that they are engaged in the management and/or support of the health, care and/or wellbeing of populations within the UK or for which they are responsible: 7.2.1 The National Health Service Commissioning Board (known as NHS England); 7.2.2 any other ‘Health service body’ as defined at section 9 of the National Health Service Act 2006 (herein referred to as “NHS Bodies” and “NHS Body” in this DPS Framework Agreement), including but not limited to: 7.2.2.1 a Clinical Commissioning Group; 7.2.2.2 an NHS Trust; 7.2.2.3 a Special Health Authority; 7.2.2.4 The Care Quality Commission; 7.2.2.5 The Secretary of State; 7.2.2.6 a Local Health Board; 7.2.2.7 a Health Board or Special Health Board constituted under section 2 of the National Health Service (Scotland) Act 1978; 7.2.2.8 a Health and Social Services Board constituted under the Health and Personal Social Services (Northern Ireland) Order 1972 (SI 1972/1265 (NI14)); 7.2.2.9 the Common Services Agency for the Scottish Health Service; 7.2.2.10 the Wales Centre for Health; 7.2.2.11 the Scottish Dental Practice Board; 7.2.2.12 the Welsh Ministers; 7.2.2.13 the Scottish Ministers, 7.2.2.14 Healthcare Improvement Scotland; 7.2.2.15 the Northern Ireland Central Services Agency for the Health and Social Services established under the Health and Personal Social Services (Northern Ireland) Order 1972; 7.2.2.16 a special health and social services agency established under the Health and Personal Social Services (Special Agencies) (Northern Ireland) Order 1990 (SI 1990/247 (NI3)); 7.2.2.17 a Health and Social Services trust established under the Health and Personal Social Services (Northern Ireland) Order 1991 (SI 1991/194 (NI1)); 7.2.2.18 the Department of Health, Social Services and Public Safety (a body of the Northern Ireland Executive) 7.2.3 NHS Foundation Trusts; 7.2.4 Academic Health Science Networks; 7.2.5 National Institute for Health and Care Excellence, known as NICE; 7.2.6 The Health and Social Care Information Centre, known as NHS Digit...
Sample 1
Participating Authorities. 7.1 The following Contracting Authorities are entitled to place Orders: 7.1.1 Salisbury NHS Foundation Trust and all bodies listed below 7.1.2 Central Government Departments, Local Government and Public Corporations : 7.1.3 xxxxx://xxx.xxx.xx/government/organisations‌ 7.1.4 Please note Central Government departments may be subject to Government Digital Service approval before using the Framework Agreement. 7.1.5 Local Authorities (England and Wales) 7.1.6 xxxxx://xxxxxx.xxxxxxxxxx.xxxxxxx.xxx.xx/government/uploads/system/uploa ds/attachment_data/file/791684/List_of_councils_in_England_2019.pdf 7.1.7 National Parks Authorities 7.1.9 Educational Establishments in England and Wales, maintained by the Department for Education including Schools, Universities and Colleges listed : 7.1.10 xxxxx://xxx.xxxxxxx-xxxxxx-xxxxxxxxxxx.xxxxxxx.xxx.xx/schools-by- type?step=default&table=schools&region=all-england&for=secondary 7.1.11 Police Forces listed by the College of Policing, plus Police Scotland and Police Service of Northern Ireland 7.1.12 xxxxx://xxx.xxxxxxx.xxxxxx.xx/About/Copyright_Licensing/Pages/Home-Office-police- forces.aspx 7.1.13 Police Forces and Special Police Forces in the United Kingdom, and/or Police and Crime Commissioners (as defined by the Police Reform and Social Responsibility Act 2011) and/or the Police Authorities (as defined in the Police Act 1964, Police Act 1996, Serious Organised Crime and Police Act 2005, Police and Justice Act 2006, Police, Public Order and Criminal Justice (Scotland) Act 2006), and other relevant legislation for the constituent parts of the United Kingdom, for their respective rights and interests 7.1.14 Fire and Rescue Services in the United Kingdom‌ 7.1.15 xxxx://xxx.xxxxxxxxxxx.xx.xx/information/ukfrs 7.1.16 xxxx://xxx.xxxxx.xxx/areas-districts/ 7.1.17 xxxx://xxx.xxxxxxxxxxxx.xxx.xx/your-area.aspx 7.1.18 NHS Bodies England
Sample 1
Participating Authorities. 7.1 The Contracting Authorities referred to in Schedule 8 are entitled to place Orders.
Sample 1
Participating Authorities. This framework agreement is for the benefit of all NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) within England, Scotland and Wales and the following other named organisations within the United Kingdom that may choose to participate at their own discretion:
Sample 1
Participating Authorities. 7.1 The following Contracting Authorities are entitled to place Orders: 8.1 The following quality assurance standards shall apply, as appropriate, to the provision of the Services: ISO 14001, ISO 9001 The Supplier shall put in place and maintain in force the following insurances with the following minimum cover per claim:
Sample 1
AutoNDA by SimpleDocs
Participating Authorities 
Sample 1

Related to Participating Authorities

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package or the Prospectus, each of the Company and its subsidiaries: (a) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”); (b) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (c) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (d) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (e) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (f) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials material to the Company and its subsidiaries taken as a whole, and conducted by or on behalf of the Company and each of its subsidiaries, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its subsidiaries has received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are material to the Company and its subsidiaries taken as a whole.

  • Competent Authorities The Parties shall inform each other about the structure, organisation and division of competences of their competent authorities during the first meeting of the Sanitary and Phytosanitary Sub-Committee referred to in Article 65 of this Agreement ("SPS Sub-Committee"). The Parties shall inform each other of any change of the structure, organisation and division of competences, including of the contact points, concerning such competent authorities.

  • Signing Authority Will the above-named Partner be able to sign contracts on behalf of the Partnership? ☐ Yes ☐ No Partner 2: with a mailing address of . a.) Ownership: %

  • Contracting authority The contracting authority of this public contract is Enabel, the Belgian development agency, public-law company with social purposes, with its registered office at Xxx Xxxxx 000, 0000 Xxxxxxxx xx Xxxxxxx (enterprise number 0264.814.354, RPM/RPR Brussels). Enabel has the exclusive competence for the execution, in Belgium and abroad, of public service tasks of direct bilateral cooperation with partner countries. Moreover, it may also perform other development cooperation tasks at the request of public interest organisations, and it can develop its own activities to contribute towards realisation of its objectives. For this procurement contract, Xxxxxx is represented by person(s) who shall sign the award letter and are mandated to represent the organisation towards third parties.

  • AUTHORITIES Intergovernmental Personnel Mobility Act, 5 U.S.C. §§ 3371-3376 • Executive Order 13171, Hispanic Employment in the Federal Government • Executive Order 13518, Employment of Veterans in the Federal Government • Executive Order 13548, Increasing Federal Employment of Individuals with Disabilities • Executive Order 13555, White House Initiative on Educational Excellence for Hispanics • Executive Order 13562, Recruiting and Hiring Students and Recent Graduates • Executive Order 13583, Establishing a Coordinated Government-wide Initiative to Promote Diversity and Inclusion in the Federal Workforce • Executive Order 13592, Improving American Indian and Alaska Native Educational Opportunities and Strengthening Tribal Colleges and Universities • Executive Order 13621, White House Initiative on Educational Excellence for African Americans • Executive Order 13779, White House Initiative to Promote Excellence and Innovation at Historically Black Colleges and Universities (HBCU) • Executive Order 13872, Economic Empowerment of Asian Americans, and Pacific Islanders • Any other superseding and subsequent authorities

  • Governmental Authorities From the date of this Agreement and until the End Date, the Company shall duly observe and conform in all material respects to all valid requirements of governmental authorities relating to the conduct of its business or to its properties or assets.

  • Cooperation with supervisory authorities 1. The data exporter agrees to deposit a copy of this contract with the supervisory authority if it so requests or if such deposit is required under the applicable data protection law. 2. The parties agree that the supervisory authority has the right to conduct an audit of the data importer, and of any subprocessor, which has the same scope and is subject to the same conditions as would apply to an audit of the data exporter under the applicable data protection law. 3. The data importer shall promptly inform the data exporter about the existence of legislation applicable to it or any subprocessor preventing the conduct of an audit of the data importer, or any subprocessor, pursuant to paragraph 2. In such a case the data exporter shall be entitled to take the measures foreseen in Clause 5 (b).

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • SUBMISSIONS You acknowledge and agree that any questions, comments, suggestions, ideas, feedback, or other information regarding the Site ("Submissions") provided by you to us are non-confidential and shall become our sole property. We shall own exclusive rights, including all intellectual property rights, and shall be entitled to the unrestricted use and dissemination of these Submissions for any lawful purpose, commercial or otherwise, without acknowledgment or compensation to you. You hereby waive all moral rights to any such Submissions, and you hereby warrant that any such Submissions are original with you or that you have the right to submit such Submissions. You agree there shall be no recourse against us for any alleged or actual infringement or misappropriation of any proprietary right in your Submissions.

  • Appointing Authority If the grievance is not settled under Step 1, it may be formally submitted to the appointing authority. The grievance shall be submitted within seven (7) days after receipt of the written decision from Step 2 or the verbal decision of Step 1, whichever applies. Within seven (7) days after receipt of the written grievance, the appointing authority or designated representative shall meet with the employee. Within seven (7) days thereafter, a written decision shall be delivered to the employee.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!